Chanjuan Zheng, Hui Yao, Lu Lu, Hongqi Li, Lei Zhou, Xueyan He, Xi Xu, Hongzhuo Xia, Siyu Ding, Yiyuan Yang, Xinyu Wang, Muyao Wu, Lian Xue, Sisi Chen, Xiaojun Peng, Zhongyi Cheng, Yian Wang, Guangchun He, Shujun Fu, Evan T Keller, Suling Liu, Yi-Zhou Jiang, Xiyun Deng
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with limited effective therapeutic options readily available. We have previously demonstrated that lovastatin, an FDA-approved lipid-lowering drug, selectively inhibits the stemness properties of TNBC. However, the intracellular targets of lovastatin in TNBC remain largely unknown. Here, we unexpectedly uncovered ribosome biogenesis as the predominant pathway targeted by lovastatin in TNBC. Lovastatin induced the translocation of ribosome biogenesis-related proteins including nucleophosmin (NPM), nucleolar and coiled-body phosphoprotein 1 (NOLC1), and the ribosomal protein RPL3...
2024: International Journal of Biological Sciences